Fidelity Investments’s ADC Therapeutics ADCT Stock Holding History

Fidelity Investments’s Portfolio ADCT Stock Details ADCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$219K	Buy	179,171 +46,396	+35%	+$54.2K	﹤0.01%	3659
2026 Q2	$142K	Sell	132,775 -39,903	-23%	-$116K	﹤0.01%	3818
2026 Q1	$648K	Buy	172,678 +38,881	+29%	+$153K	﹤0.01%	3019
2025 Q4	$472K	Buy	133,797 +370	+0.3%	+$1.5K	﹤0.01%	3107
2025 Q3	$534K	Buy	133,427 +1,562	+1%	+$4.92K	﹤0.01%	3006
2025 Q2	$353K	Sell	131,865 -4,551	-3%	-$9.6K	﹤0.01%	3103
2025 Q1	$192K	Buy	136,416 +9,397	+7%	+$16K	﹤0.01%	3264
2024 Q4	$253K	Buy	127,019 +73,977	+139%	+$194K	﹤0.01%	3178
2024 Q3	$167K	Buy	+53,042	New	+$167K	﹤0.01%	3260
2024 Q1	–	Sell	-6	Closed	-$10	–	5342
2023 Q4	$10	Sell	6 -1,309	-100%	-$1.21K	﹤0.01%	5314
2023 Q3	$1.18K	Sell	1,315 -67	-5%	-$89	﹤0.01%	4630
2023 Q2	$2.97K	Sell	1,382 -39,062	-97%	-$87.8K	﹤0.01%	4499
2023 Q1	$78.9K	Sell	40,444 -4,613,009	-99%	-$17M	﹤0.01%	3276
2022 Q4	$17.9M	Sell	4,653,453 -3,019,684	-39%	-$12.1M	﹤0.01%	1657
2022 Q3	$37M	Sell	7,673,137 -7,909	-0.1%	-$57.3K	﹤0.01%	1366
2022 Q2	$61.1M	Hold	7,681,046	–	–	0.01%	1174
2022 Q1	$113M	Buy	7,681,046 +8,373	+0.1%	+$133K	0.01%	1022
2021 Q4	$155M	Hold	7,672,673	–	–	0.01%	901
2021 Q3	$208M	Hold	7,672,673	–	–	0.02%	791
2021 Q2	$187M	Sell	7,672,673 -88,912	-1%	-$2.06M	0.01%	856
2021 Q1	$189M	Hold	7,761,585	–	–	0.02%	812
2020 Q4	$248M	Buy	7,761,585 +90,000	+1%	+$2.95M	0.02%	662
2020 Q3	$253M	Buy	7,671,585 +2,427,354	+46%	+$105M	0.03%	548
2020 Q2	$245M	Buy	+5,244,231	New	+$199M	0.03%	525

Other funds holding ADCT

ACM

AIGH Capital Management Baltimore, Maryland $992M AUM 516.32% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Panagora Asset Management Boston, Massachusetts $33.2B AUM 43.67% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $294B AUM 47.59% 1-Year Est. Return

Sanibel Captiva Trust Company Sanibel, Florida $4.04B AUM 26.09% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Commerce Bank Kansas City, Missouri $22.9B AUM 22.61% 1-Year Est. Return

Fidelity Investments's ADCT Position: Q3 2026 in Review

Fidelity Investments increased its ADC Therapeutics (ADCT) stake by 35% in Q3 2026, buying an estimated $54.2K and bringing the position to 179,171 shares worth $219K. The position accounts for ﹤0.01% of the portfolio, ranked #3659.

Fidelity Investments first reported a position in ADCT in Q2 2020 and has held it in 24 quarters since. The position peaked at $253M in Q3 2020. 55 funds tracked by Wall St. Rank hold ADCT as of Q3 2026.

Fidelity Investments held 179,171 shares of ADC Therapeutics worth $219K as of Q3 2026.
Fidelity Investments bought 46,396 ADC Therapeutics shares in Q3 2026, an estimated $54.2K.
ADC Therapeutics made up ﹤0.01% of Fidelity Investments's portfolio in Q3 2026, its #3659 holding.
Fidelity Investments first reported a position in ADC Therapeutics in Q2 2020 and has held it in 24 quarters since.
Fidelity Investments's ADC Therapeutics position peaked at $253M in Q3 2020.
55 funds tracked by Wall St. Rank held ADC Therapeutics as of Q3 2026.

Based on Fidelity Investments's 13F filing for Q3 2026, filed 10 Nov 2026.